These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 1979261)

  • 1. Pyridostigmine does not reverse dexamethasone-induced growth hormone inhibition.
    del Balzo P; Salvatori R; Cappa M; Gertner JM
    Clin Endocrinol (Oxf); 1990 Nov; 33(5):605-12. PubMed ID: 1979261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of hypothalamic somatostatin by glucocorticoids.
    Devesa J; Barros MG; Gondar M; Tresguerres JA; Arce V
    J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):277-82. PubMed ID: 7626468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucocorticoids may inhibit growth hormone release by enhancing beta-adrenergic responsiveness in hypothalamic somatostatin neurons.
    Lima L; Arce V; Diaz MJ; Tresguerres JA; Devesa J
    J Clin Endocrinol Metab; 1993 Feb; 76(2):439-44. PubMed ID: 8094392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyridostigmine partially reverses dexamethasone-induced inhibition of the growth hormone response to growth hormone-releasing hormone.
    Trainer PJ; Kirk JM; Savage MO; Grossman AB; Besser GM
    J Endocrinol; 1992 Sep; 134(3):513-7. PubMed ID: 1357070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
    Arvat E; Di Vito L; Ramunni J; Gianotti L; Giordano R; Deghenghi R; Camanni F; Ghigo E
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyridostigmine blocks the inhibitory effect of glucocorticoids on growth hormone-releasing hormone stimulated growth hormone secretion in normal man.
    Giustina A; Girelli A; Doga M; Bodini C; Bossoni S; Romanelli G; Wehrenberg WB
    J Clin Endocrinol Metab; 1990 Sep; 71(3):580-4. PubMed ID: 2118535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation and neuroregulatory control of growth hormone secretion.
    Ogilvy-Stuart AL; Wallace WH; Shalet SM
    Clin Endocrinol (Oxf); 1994 Aug; 41(2):163-8. PubMed ID: 7923820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of cholinergic neurotransmission by pyridostigmine reverses the inhibitory effect of hyperglycemia on growth hormone (GH) releasing hormone-induced GH secretion in man: does acute hyperglycemia act through hypothalamic release of somatostatin?
    Peñalva A; Burguera B; Casabiell X; Tresguerres JA; Dieguez C; Casanueva FF
    Neuroendocrinology; 1989 May; 49(5):551-4. PubMed ID: 2566942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholinergic control of growth hormone (GH) responses to GH-releasing hormone in insulin dependent diabetics: evidence for attenuated hypothalamic somatostatinergic tone and decreased GH autofeedback.
    Ismail IS; Scanlon MF; Peters JR
    Clin Endocrinol (Oxf); 1993 Feb; 38(2):149-57. PubMed ID: 8094648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of pyridostigmine on spontaneous and growth hormone-releasing hormone stimulated growth hormone secretion in children on daily glucocorticoid therapy after liver transplantation.
    Giustina A; Girelli A; Alberti D; Bossoni S; Buzi F; Doga M; Schettino M; Wehrenberg WB
    Clin Endocrinol (Oxf); 1991 Dec; 35(6):491-8. PubMed ID: 1769130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GH feedback occurs through modulation of hypothalamic somatostatin under cholinergic control: studies with pyridostigmine and GHRH.
    Ross RJ; Tsagarakis S; Grossman A; Nhagafoong L; Touzel RJ; Rees LH; Besser GM
    Clin Endocrinol (Oxf); 1987 Dec; 27(6):727-33. PubMed ID: 2901302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms underlying the negative growth hormone (GH) autofeedback on the GH-releasing effect of hexarelin in man.
    Arvat E; Di Vito L; Gianotti L; Ramunni J; Boghen MF; Deghenghi R; Camanni F; Ghigo E
    Metabolism; 1997 Jan; 46(1):83-8. PubMed ID: 9005975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence that alpha 2-adrenergic pathways play a major role in growth hormone (GH) neuroregulation: alpha 2-adrenergic agonism counteracts the inhibitory effect of muscarinic cholinergic receptor blockade on the GH response to GH-releasing hormone, while alpha 2-adrenergic blockade diminishes the potentiating effect of increased cholinergic tone on such stimulation in normal men.
    Devesa J; Diaz MJ; Tresguerres JA; Arce V; Lima L
    J Clin Endocrinol Metab; 1991 Aug; 73(2):251-6. PubMed ID: 1677361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone secretion in aging. Effect of pyridostigmine on growth hormone responsiveness to growth hormone-releasing hormone.
    Giusti M; Marini G; Sessarego P; Peluffo F; Valenti S; Caratti C; Giordano G
    Recenti Prog Med; 1991 Dec; 82(12):665-8. PubMed ID: 1815302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man.
    Peñalva A; Carballo A; Pombo M; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1993 Jan; 76(1):168-71. PubMed ID: 8421084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arginine potentiates the GHRH- but not the pyridostigmine-induced GH secretion in normal short children. Further evidence for a somatostatin suppressing effect of arginine.
    Ghigo E; Bellone J; Mazza E; Imperiale E; Procopio M; Valente F; Lala R; De Sanctis C; Camanni F
    Clin Endocrinol (Oxf); 1990 Jun; 32(6):763-7. PubMed ID: 1974484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of cholinergic tone by pyridostigmine reverses the inhibitory effect of corticotropin-releasing hormone on the growth hormone-releasing hormone-induced growth hormone secretion.
    Corsello SM; Tofani A; Della Casa S; Sciuto R; Rota CA; Colasanti S; Bini A; Barini A; Barbarino A
    Acta Endocrinol (Copenh); 1992 Feb; 126(2):113-6. PubMed ID: 1543015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli.
    Peino R; Cordido F; Peñalva A; Alvarez CV; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1996 Mar; 81(3):909-13. PubMed ID: 8772549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
    Cordido F; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1989 Feb; 68(2):290-3. PubMed ID: 2493023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of glucose and pyridostigmine on the secretion of growth hormone (GH) induced by GH-releasing hormone (GHRH).
    Delitala G; Tomasi PA; Palermo M; Fresu P
    J Endocrinol Invest; 1990 Sep; 13(8):653-6. PubMed ID: 2273206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.